Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 56

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 56
---
 sales agreement, to terminate the sales agreement in each party’s sole
discretion at any time. The offering of our common stock pursuant to the sales agreement will otherwise terminate upon the termination of the sales agreement as provided therein.

The compensation payable to the sales agents will be up to 3.0% of the gross proceeds of any shares of common stock sold through it pursuant
to the sales agreement. We have also agreed to reimburse the sales agents for certain of their expenses in an amount up to $50,000. We estimate that the total expenses of the offering payable by us, excluding commissions payable to the sales agents
under the sales agreement, will be approximately $325,000.

The remaining sales proceeds, after deducting any expenses payable by us and
any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales of our common stock, will equal our net proceeds for the sale of such common stock.

The sales agents will provide written confirmation to us no later than the next succeeding trading day on the Nasdaq Global Market after each
day on which common stock is sold through the sales agents under the sales agreement. Each confirmation will include the number or amount of shares sold through the sales agents on that day, the volume weighted average price of the shares sold, the
percentage of the daily trading volume and the net proceeds to us from such sales.

We will report at least quarterly the number of shares
of common stock sold through Leerink Partners and Cantor under the sales agreement, the net proceeds to us and the compensation paid by us to Leerink Partners and Cantor in connection with the sales of common stock during the relevant period.

Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second trading day following the date on which any
sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

In connection with the sale of the common stock on our behalf pursuant to the sales agreement, Leerink Partners and Cantor may be deemed to be
an “underwriter” within the meaning of the Securities Act and the compensation paid to Leerink Partners and Cantor may be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification
and contribution to Leerink Partners and Cantor with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act. As sales agents, Leerink Partners and Cantor will